Avadel Pharmaceuticals (FRA:AWK) Total Liabilities : €86.3 Mil (As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Avadel Pharmaceuticals Total Liabilities?

Avadel Pharmaceuticals's Total Liabilities for the quarter that ended in Dec. 2024 was €86.3 Mil.

Avadel Pharmaceuticals's quarterly Total Liabilities declined from Jun. 2024 (€81.04 Mil) to Sep. 2024 (€75.32 Mil) but then increased from Sep. 2024 (€75.32 Mil) to Dec. 2024 (€86.32 Mil).

Avadel Pharmaceuticals's annual Total Liabilities declined from Dec. 2022 (€145.31 Mil) to Dec. 2023 (€70.57 Mil) but then increased from Dec. 2023 (€70.57 Mil) to Dec. 2024 (€86.32 Mil).

Avadel Pharmaceuticals Total Liabilities Historical Data

The historical data trend for Avadel Pharmaceuticals's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avadel Pharmaceuticals Total Liabilities Chart

Avadel Pharmaceuticals Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Liabilities

Get a 7-Day Free Trial

122.78

149.58

145.31

70.57

86.32

Avadel Pharmaceuticals Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Total Liabilities	Get a 7-Day Free Trial															70.57	82.35	81.04	75.32	86.32

Avadel Pharmaceuticals Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Avadel Pharmaceuticals's Total Liabilities for the fiscal year that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	46.636	+	(1.072	+	33.694
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	4.919)
	=	86.3

Total Liabilities	=	Total Assets (A: Dec. 2024 )	-	Total Equity (A: Dec. 2024 )
	=	156.845	-	70.525
	=	86.3

Avadel Pharmaceuticals's Total Liabilities for the quarter that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	46.636	+	(1.072	+	33.694
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	4.919)
	=	86.3

Total Liabilities	=	Total Assets (Q: Dec. 2024 )	-	Total Equity (Q: Dec. 2024 )
	=	156.845	-	70.525
	=	86.3

Avadel Pharmaceuticals Total Liabilities Related Terms

Thank you for viewing the detailed overview of Avadel Pharmaceuticals's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Avadel Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Avadel Pharmaceuticals PLC (FRA:AWK) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

AVDL:USA

Address

10 Earlsfort Terrace, Dublin 2, Dublin, IRL, D02 T380

Website

https://www.avadel.com

Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. The group focused on transforming medicines to transform lives. It provides solutions to the development of medications that address the challenges patients face with current treatment options. The company is engaged in the development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy. It operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer-based technology.